After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms.
Behind the structural shift is a convergence of new leadership, complementary technology platforms involving the brain-immune-gut axis and a strong financial position.
The internal pipeline brings together three nascent platforms focused around the lymphatic system, plus two immuno-oncology programs: one targeting a subset of γδ T cells, and the other against a novel target that modulates the immunosuppressive activity of macrophages.
PureTech also unveiled a deal last year with Roche to use milk-derived exosomes to deliver the pharma’s antisense oligonucleotides, underpinning the biotech’s new approach.
PureTech CSO Joseph Bolen said a major driver for the shift to an internal platform was the synergy between the exosome platform and the two other lymphatic programs, one of which involves lymphatic-based drug delivery, the other of which modulates brain lymphatics.
“What’s been clear to everyone is that solutions to the problems we’re working on now require multiple technologies to be brought together for the best chance of making a medicine. When you have to bring multiple technologies together, it’s difficult to do that in an affiliate model,” he said.
PureTech was founded in 2001 and since 2004 has operated an affiliate model that involves finding innovative biology, creating an entity around it, and managing the company until it was advanced enough to seek external financing. PureTech would contribute about $100,000